Endothelin-receptor antagonism: the future is bright

The Lancet

Volumn 371, Issue 9630, 2008, Pages 2061-2062

  Dhaun, Neeraj ^a   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ATRASENTAN; BOSENTAN; CLAZOSENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; PLACEBO; PROSTANOID; SILDENAFIL; SITAXSENTAN; TEZOSENTAN;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DIABETIC NEPHROPATHY; DIASTOLIC HEART FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CANCER; LUNG FIBROSIS; OVARY CANCER; PERITONEUM CANCER; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROSTATE CANCER; PULMONARY HYPERTENSION; SCLERODERMA; SUBARACHNOID HEMORRHAGE; UTERINE TUBE TUMOR;

EID: 45249097125     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60895-8     Document Type: Note

References (9)

1. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415
2. Dupuis J., and Hoeper M. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 31 (2008) 407-415
3. Galiè N., Rubin L., Hoeper M., et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled study (EARLY study). Lancet 371 (2008) 2093-2100
4. McLaughlin V., Oudiz R., Frost A., et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174 (2006) 1257-1263
5. Channick R., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001) 1119-1123
6. Rubin L., Badesch D., Barst R., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
7. Barst R., Langleben D., Badesch D., et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47 (2006) 2049-2056
8. Dhaun N., Pollock D., Goddard J., and Webb D. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci 28 (2007) 573-579
9. Galiè N., Badesch D., Oudiz R., et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46 (2005) 529-535